Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• The Indoleamine-2,3-dioxygenase (IDO1) pathway promotes cancer immune escape and immunosuppression, correlating with poor prognosis in melanoma.
• Nanoliposomal Epacadostat (Lip-EPA) has demonstrated antitumoral efficacy as an IDO1 inhibitor.
• Combination therapy represents a promising strategy to overcome treatment resistance in cancer.

Purpose of the Study:

• To evaluate the combined therapeutic effect of Lip-EPA and a liposomal gp100 anti-cancer vaccine (Lip-gp100) in a melanoma model.
• To investigate the impact of this combination therapy on the tumor microenvironment and immune response.
• To assess the potential of this novel combination for future clinical applications.

Main Methods:

• B16F10 melanoma cells were used to establish tumors in a preclinical model.
• Lip-EPA was administered in combination with Lip-gp100, and its biodistribution was tracked using ICG-labeling.
• Tumor samples were analyzed for IDO1 mRNA expression, T lymphocyte infiltration, interferon-gamma (IFN-γ) production, and regulatory T cell populations.

Main Results:

• Lip-EPA demonstrated significant accumulation at the tumor site.
• The combination therapy led to a fourfold decrease in IDO mRNA expression within tumors.
• A significant increase in infiltrated T lymphocytes and IFN-γ production was observed (p < 0.0001).
• Intratumoral regulatory T cells were modulated, resulting in a 56.54% delay in tumor growth and >47.36% increase in lifespan.

Conclusions:

• The combination of Lip-EPA and Lip-gp100 significantly enhances anti-tumor efficacy in melanoma by modulating the immune microenvironment.
• This novel therapeutic strategy effectively suppresses IDO1 activity and boosts anti-tumor immune responses.
• The demonstrated efficacy and safety profile suggest this combination is a promising candidate for further clinical investigation.